Top Healthcare Companies

Ge Healthcare Technologies Inc. (GEHC) has a forecasted full-year revenue of $882B, based on 16 quarters of SEC filing data.

Revenue is driven primarily by R&D-led product development, with SG&A contributing more modestly to the top line.

Our econometric model projects McKesson FY revenue near $499B with a +24% YoY forecast; the holdout is tight (predicted $107B vs actual $106B), and MAPE sits around 2%. SG&A ROI of about $25.7 in revenue per $1 spent suggests SG&A is a strong revenue lever rather than a drag, aligning with McKesson’s integrated distribution and services model.

Our econometric model uses a linear framework with fixed coefficients estimated over 70 quarters, and the time-varying view shows SG&A spending becoming more productive: SG&A ROI sits at $4.44 in revenue per $1 spent, while the SG&A multiplier rises from 0.06 to 0.14, implying growth is increasingly driven by operating spending and scale rather than one-off pricing moves.

Our econometric model delivers a 3.5% MAPE and a holdout error of -0.1% for Cencora, Inc. (COR), indicating strong forecasting accuracy.

Elasticity analysis shows SG&A spending drives revenue with an elasticity of 0.89, meaning a 1% rise in SG&A is associated with roughly a 0.89% increase in revenue.

Latest quarterly revenue is $72.5 billion, supported by a historical data set spanning 32 quarters.

Humana's revenue is forecast to grow about 9% year over year to roughly $155 billion, driven by steady Medicare Advantage enrollment and premium actions.

Latest quarterly revenue came in at $23.25 billion, with a full-year forecast of $94 billion representing about 2.7% year-over-year growth.

[AI commentary unavailable].

[AI commentary unavailable].

Revenue growth is driven by SG&A investments, with a 1% rise in SG&A associated with a 0.86% increase in revenue, indicating a strong ROI on selling and marketing spend.

[AI commentary unavailable].

[AI commentary unavailable].

[AI commentary unavailable].

[AI commentary unavailable].

[AI commentary unavailable].

Latest quarterly revenue stood at $9.866 billion.

Revenue is driven by SG&A spending, with a near-unity elasticity of 1.04% revenue for a 1% SG&A increase, as estimated by a log-log model; the latest quarterly revenue is $9.017B.

Stryker is on track for roughly 21% revenue growth next year, lifting FY revenue to about $36.5 billion from $30.3 billion.

Revenue is predominantly driven by core product sales, with the latest quarterly revenue at about $8.31 billion and a 60-quarter data history underpinning the model.

[AI commentary unavailable].

Revenue is set to grow roughly 19% year over year, with next-year revenue around $28 billion as Boston Scientific benefits from a healthy product cycle and stronger market uptake across its device portfolio.

[AI commentary unavailable].

Revenue growth is driven predominantly by SG&A spending, which the model ties to a 1.00 elasticity (a 1% SG&A increase yields roughly a 1% revenue gain), while R&D shows a more modest 0.26 elasticity.

[AI commentary unavailable].

Revenue is driven by a modest positive response to SG&A spending, with a 1% increase in SG&A yielding about a 0.28% rise in revenue, per the log-log model.

[AI commentary unavailable].

[AI commentary unavailable].

SG&A investments drive revenue, with an elasticity of 0.63% in revenue for every 1% change in SG&A, while R&D impact is not quantified in this dataset.

[AI commentary unavailable].

[AI commentary unavailable].

Revenue is expected to rise about 17% year over year to roughly $13.8 billion, supported by a growing installed base of da Vinci systems and higher utilization in existing markets.

Revenue is expected to grow only modestly this year, up about 0.4% year over year to roughly $11.1 billion, reflecting a stable demand base for core diagnostic testing.

Under the model, SG&A spending is a positive driver of long-run revenue, with a ROI of about 4.78 in revenue per dollar, while R&D spending is modeled as a negative driver, subtracting roughly 7.10 in long-run revenue per dollar.

The revenue model shows SG&A spending has higher revenue elasticity than R&D, with a 1% increase in SG&A associated with a 1.22% revenue lift versus 0.80% for 1% R&D, indicating SG&A investments currently yield stronger revenue leverage.

[AI commentary unavailable].

[AI commentary unavailable].

[AI commentary unavailable].

Revenue is driven more by SG&A spending than R&D, with elasticity estimates of 1.10% revenue per 1% SG&A increase and 0.45% per 1% R&D increase, indicating SG&A investments deliver the larger marginal lift.

[AI commentary unavailable].

[AI commentary unavailable].

[AI commentary unavailable].

Revenue growth is driven by SG&A efficiency, as each dollar of SG&A spending is modeled to generate $2.46 in long-run revenue, compared with $0.75 from R&D investments.

[AI commentary unavailable].

[AI commentary unavailable].

[AI commentary unavailable].

For investors evaluating West Pharmaceutical Services Inc. (WST), revenue is modeled as a linear mix of spending on R&D and SG&A, with each dollar of R&D tied to a long-run revenue delta of -19.29 and each dollar of SG&A tied to +11.35.

[AI commentary unavailable].

[AI commentary unavailable].